Alembic Pharmaceuticals Limited announces USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension.
Ahmedabad 11th, December: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3% (5 mL and 10 mL). The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet…
